BP agrees 0234 GMT [Dow Jones] The publication of Mesoblast's...

BP agrees



0234 GMT [Dow Jones] The publication of Mesoblast's (MSB.AU) results from its
Phase II congenital heart failure study in the peer-reviewed American Heart Association
journal Circulation provides further validation of the methodology used, as well as the
conclusions reported from the study, says Bell Potter. Analyst Tanushree Jain says the
results have now undergone multiple validations which should serve to reassure investors
about their integrity. Notes interim results of a Phase III trial are expected in the
first quarter of calendar 2016, which seems an achievable timeline given the trial is
recruiting well across North America, Jain says in a research note. Maintains Buy rating.
([email protected]; @beckthurlow)

Editor: CNG


(END) Dow Jones Newswires
July 15, 2015 22:34 ET (02:34 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Thursday 16 July 2015 12:34:00.000 AEST